Key Highlights

  • Ionis Pharmaceuticals (NASDAQ: IONS) received FDA approval for Zanvastro in Alexander disease, with a U.S. launch expected within weeks.
  • Summit Therapeutics (NASDAQ: SMMT) rose 17% and Hutchmed (NASDAQ: HCM) rose 17% on positive trial data and a new GSK licensing deal, respectively.
  • Ultragenyx (NASDAQ: RARE) fell 44% on an Angelman syndrome trial miss, while Medicus Pharma (NASDAQ: MDCX) and Aptevo Therapeutics (NASDAQ: APVO) each fell 34% despite new deal and data disclosures.
  • Several smaller names, including Immuron (NASDAQ: IMRN), Clearmind Medicine (NASDAQ: CMND), Modular Medical (NASDAQ: MODD), and Senti Biosciences (NASDAQ: SNTI), advanced distribution, acquisition, regulatory, and financing updates.

Biotech news over September 3 and 4, 2026 spanned a wide range of developments, from a new FDA approval and a major licensing deal to a clinical trial miss and several financing and corporate updates across more than a dozen companies.

Regulatory Wins and Approvals

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) received FDA approval for Zanvastro to treat Alexander disease in both children and adults, backed by Phase 1-3 results showing stabilized gait speed in patients aged five and up and improved gross motor function in younger populations. The drug earned a Rare Pediatric Disease Priority Review Voucher, with a U.S. commercial launch expected within weeks.

Modular Medical, Inc. (NASDAQ: MODD) secured FDA 510(k) clearance for software updates to its Pivot tubeless insulin pump, enhancing user-interface features and bolus delivery Options ahead of a limited commercial rollout across five domestic territories starting in October 2026.

Aptevo Therapeutics, Inc. (NASDAQ: APVO) reported interim RAINIER data in frontline TP53-mutated AML showing a 93% clinical benefit rate and 79% CR/CRi among 14 evaluable patients treated with mipletamig plus venetoclax and azacitidine, comparing favorably to a published 41% benchmark, though shares closed down 34% at $1.71 despite the data. Dose optimization is expected to complete by year-end, with regulatory interaction planned in the first half of 2027.

Licensing and M&A Activity

Hutchmed (China) Limited (NASDAQ: HCM) shares closed up 17% at $14.11 after the company entered an exclusive ex-China license with GSK for HMPL-A830, receiving $110 million upfront and up to $1.3 billion in total milestones plus royalties. Hutchmed will lead global Phase 1 development starting in the second half of 2026 before GSK assumes later-stage responsibilities.

Medicus Pharma Ltd. (NASDAQ: MDCX) shares closed down 34% at $0.17 despite entering a worldwide licensing agreement with Pfizer for the early-stage CD228V antibody-drug conjugate PF-08046031, which includes $12 million upfront, a $15 million anniversary payment, $2 million in restricted R&D funding, and potential milestone obligations surpassing $1 billion plus royalties.

Clearmind Medicine Inc. (NASDAQ: CMND) entered a definitive agreement to acquire a 51% stake in EV wireless charging company Charging Robotics for $2.5 million plus a $1.5 million loan, a Diversification move away from its psychedelic therapeutics focus shortly after initiating Phase 2a testing of CMND-100 in alcohol use disorder.

Immuron Limited (NASDAQ: IMRN) entered an exclusive U.S. distribution agreement with Calmino Group AB for PROIBS, a European-certified medical device for digestive symptoms, broadening its lineup alongside its existing Travelan product.

Clinical Setbacks and Data Readouts

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares closed down 44% at $14.85 after its Angelman syndrome trial failed to meet its primary endpoint, even as the company's recently approved GSDIa therapy, backed by Phase 3 GENGLYCOS results, continues to show separate progress.

Summit Therapeutics Inc. (NASDAQ: SMMT) shares closed up 17% at $17.13 after partner Akeso reported Chinese Phase 3 data showing ivonescimab improved survival compared to Merck's Keytruda in lung cancer patients, with the full data set expected September 15 ahead of the global HARMONi-3 readout slated for late 2026.

bioAffinity Technologies, Inc. (NASDAQ: BIAF) shares closed up 31% at $12.78 as the company advances its CyPath Lung platform for post-therapeutic lung cancer monitoring, aiming to augment standard CT scans with a noninvasive malignancy-risk assessment, though current accuracy data reflects early-detection performance rather than validation in a recurrence-specific setting.

Financing, Corporate, and Listing Updates

Senti Biosciences, Inc. (NASDAQ: SNTI) raised $2 million via senior secured convertible notes issued to NSG BioInnovation Fund and established a $2.5 million Equity agreement with a Celadon affiliate contingent on its pending merger.

BioRestorative Therapies, Inc. (NASDAQ: BRTX) shares closed down 29% at $0.14 ahead of a scheduled 1-for-20 Reverse Stock Split effective September 7, 2026, with post-split trading set to begin September 8.

Aethlon Medical, Inc. (NASDAQ: AEMD) secured a USPTO notice of allowance for a Patent covering technology to manage viral infections and their symptoms, bolstering intellectual property around its Hemopurifier system.

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) Chief Legal Officer Scott Bizily executed a routine sequence of option exercises and sales involving 584 shares at prices between $6.49 and $14, leaving a direct stake of 8,617 shares.

Separately, US markets were scheduled to be closed Monday, September 7, 2026, in observance of Labor Day.